- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Inhibikase Therapeutics Inc.
Headquarters: Atlanta, GA, United States of America
Website: http://www.inhibikase.com
Year Founded: 2008
Status: Public
Industry Sector: HealthTechnology
CEO: Mark T. Iwicki, MBA
Number Of Employees: 8
Enterprise Value: $-5,857,017
PE Ratio: -0.81
Exchange/Ticker 1: NASDAQ:IKT
Exchange/Ticker 2: N/A
Latest Market Cap: $152,597,312
BioCentury | Feb 25, 2025
Management Tracks
After leaving FDA, Cavazzoni joins Pfizer as CMO
Plus: CFO hires at Nuclera, Crinetics, Terns and updates from Xeris, Inhibikase and Climb Bio
BioCentury | Oct 11, 2024
Finance
Upstream catches aftermarket updraft, as Camp4 IPO gets muted reception
BioCentury’s weekly Public Equity Report also includes financings by Crinetics, Scholar Rock, Immatics, Inhibikase and Vicore
BioCentury | Jan 18, 2024
Management Tracks
Paul stepping down as Karuna CSO
Plus: leadership changes at Valo and more from Mirum, Arvinas, Vaxcyte, Lantern and Inhibikase
BioCentury | Dec 31, 2020
Finance
Dec. 30 Quick Takes: Transcenta leads year-end crop of China venture rounds
Transcenta rounds out year with $105M crossover roundTranscenta Holding Ltd. raises $105 million in a crossover round led by China Structural Reform Fund. New investors Country Garden Venture
BioCentury | Jan 18, 2018
Emerging Company Profile
Computing brain entry
How 1st Biotherapeutics is applying computational tools to CNS drug discovery
BioCentury | Dec 14, 2017
Product R&D
Opening doors in PML
How NIH and Neurimmune are collaborating and competing in PML
Items per page:
1 - 8 of 8